- Home
- ASC vs KALV Comparison
ASC vs KALV Comparison
Compare ASC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASC
- KALV
- Stock Information
- Founded
- ASC 2010
- KALV N/A
- Country
- ASC Bermuda
- KALV United States
- Employees
- ASC N/A
- KALV N/A
- Industry
- ASC Marine Transportation
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- ASC Consumer Discretionary
- KALV Health Care
- Exchange
- ASC Nasdaq
- KALV Nasdaq
- Market Cap
- ASC 501.8M
- KALV 796.4M
- IPO Year
- ASC 2013
- KALV N/A
- Fundamental
- Price
- ASC $13.28
- KALV $13.38
- Analyst Decision
- ASC Buy
- KALV Strong Buy
- Analyst Count
- ASC 3
- KALV 8
- Target Price
- ASC $12.67
- KALV $26.43
- AVG Volume (30 Days)
- ASC 485.8K
- KALV 984.5K
- Earning Date
- ASC 11-05-2025
- KALV 09-11-2025
- Dividend Yield
- ASC 7.15%
- KALV N/A
- EPS Growth
- ASC N/A
- KALV N/A
- EPS
- ASC 1.04
- KALV N/A
- Revenue
- ASC $324,200,000.00
- KALV $1,426,000.00
- Revenue This Year
- ASC N/A
- KALV N/A
- Revenue Next Year
- ASC N/A
- KALV $213.43
- P/E Ratio
- ASC $12.76
- KALV N/A
- Revenue Growth
- ASC N/A
- KALV N/A
- 52 Week Low
- ASC $8.32
- KALV $7.30
- 52 Week High
- ASC $18.79
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- ASC 83.41
- KALV 43.21
- Support Level
- ASC $12.06
- KALV $13.26
- Resistance Level
- ASC $13.34
- KALV $14.25
- Average True Range (ATR)
- ASC 0.36
- KALV 1.03
- MACD
- ASC 0.11
- KALV -0.15
- Stochastic Oscillator
- ASC 91.44
- KALV 3.70
About ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.